Cuorips (4894) · InitiativeAdvanced
Improving safety through high-purity purification and removal of undifferentiated iPS cells
First written in FY2023. 1 of 2 entries say "Advanced", first in FY2024. Latest entry: FY2024.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Safety Management in Regenerative Medicine Through Purification and ImmunosuppressionA theme 3 companies write about · 1 as a headwind · 2 as a tailwind
0 other companies' latest entry also says "Advanced".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2024AdvancedAnnual report
「Using our proprietary purification technology for removing undifferentiated iPS cells, we seek to reduce the risk of tumorigenesis arising from residual undifferentiated iPS cells. No report has been made of tumors derived from the product in patients who received transplantation in the investigator-initiated clinical trial currently being conducted at Osaka University.」
In addition to reducing tumorigenesis risk through removal of undifferentiated cells, the company disclosed that no product-derived tumors had been reported in the investigator-initiated clinical trial. - FY2023First statedAnnual report
「Using our proprietary purification technology for removing undifferentiated iPS cells, we seek to reduce the risk of tumorigenesis arising from residual undifferentiated iPS cells.」
The company describes as a strength its technology for mass-producing high-purity cardiomyocytes and removing residual undifferentiated cells below the detection limit.